Results 221 to 230 of about 444,966 (303)

Repurposing the Tyrosine Kinase Inhibitors Targeting FGFR and VEGFR Pathways for Cancer Therapy: A Comprehensive Review. [PDF]

Cancers (Basel)
Boichuk S, Gessel T.
europepmc   +1 more source

Biomimetic Nanomedicine for Senescence‐Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Advanced Science, EarlyView.
A multifunctional mPDZM nanoplatform is developed in this study. mPDZM integrates chemotherapy‐induced senescence, selective senolysis, and STING‐mediated immune activation. mPDZM effectively clears senescent tumor cells, remodels the tumor immune microenvironment, and enhances antitumor T‐cell responses.
Shiji Fang, Liyun Zheng, Bin Lin, Jiale Chen, Dehai Hou, Yiming Ding, Mengzhu Han, Pan Qin, Mengyuan Wang, Xiaoju Guo, Yeyu Zhang, Gaofeng Shu, Fazong Wu, Jianfei Tu, Minjiang Chen, Zhongwei Zhao, Zhuang Liu, Jiansong Ji   +17 more
wiley   +1 more source

Comparison of One-Year Adverse Events Between First- and Second-Generation Bruton's Tyrosine Kinase Inhibitors: A Retrospective Study. [PDF]

Cureus
Ito A, Ito K, Iriyama C, Goto N, Inamoto Y, Okamoto M, Hirose Y, Morisaku M, Yamada S, Hayakawa N, Tomita A.   +10 more
europepmc   +1 more source

Tyrosine Kinase Inhibitor XL228 [PDF]

, 2020
openaire   +1 more source

AXL Promotes Ischemic Myelin Repair Through Alleviating Myelin Debris Deposition and Lipid Droplets Accumulation

Advanced Science, EarlyView.
Microglial AXL drives white matter repair after stroke by orchestrating the cleanup of myelin debris. Mechanistically, AXL signals through EGR1 to boost Smpd1 transcription, regulating sphingolipid metabolism and preventing lipid droplet toxicity. Restoring the pathway with ASM therapy mitigates damage, positioning AXL as a key node for therapeutic ...
Junqiu Jia, Yonghui Gan, Jia Li, Lilin Li, Hailan Meng, Min Sun, Lei Ye, Rui Mao, Xiang Cao, Shengnan Xia, Xinyu Bao, Renyuan Liu, Meijuan Zhang, Yun Xu   +13 more
wiley   +1 more source

Bibliometric analysis of hepatocellular carcinoma and tyrosine kinase inhibitors. [PDF]

Medicine (Baltimore)
Wu W, Mao H, Song J, Yang F.
europepmc   +1 more source

Hepatocyte BPGM Induces RET Lactylation and Macrophage Reprogramming to Promote Tumorigenesis in Hepatocellular Carcinoma

Advanced Science, EarlyView.
Mechanistic schematic diagram.BPGM promotes the expression level of RET by increasing the lactylation of RET‐K549 and inhibiting its ubiquitination levels in HCC cells. Furthermore, BPGM in HCC cells could also promote M2 polarization in macrophages through lactate secretion. Both of the mechanisms could promote the progression of HCC. ABSTRACT Aerobic
Jiajia Zhang, Lu Shi, Liangliang Lin, Yang Zhang, Miao Zhang, Lili Wu, Yong Xia, Yaqiong Zhang, Peng Han, Likun Zhuang, Liang Shi   +10 more
wiley   +1 more source

Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor After Imatinib Resistance. [PDF]

Pharmaceutics
Xiao XH, Zhang QS, Hu JY, Zhang YX, Song H.   +4 more
europepmc   +1 more source

Synthetic Lethal Therapy Based on Dimorphism for Systemic Infection of Drug‐Resistant Candida albicans

Advanced Science, EarlyView.
To tackle the alarming mortality rate linked to Candida albicans infections, a synthetic lethal strategy precisely aimed at the two distinct forms of this fungus: yeast and hyphae is formulated. Ultimately, through the innovative use of macrophage membranes for drug delivery, the effectiveness of this strategy is substantially boosted while ...
Yang Gao, Jiahe Su, Jiawei Yuan, Qinyan Cao, Yue Wu, Yuyang Xiao, Guang Yang, Ruomu Xia, Jingpeng Yang, Yanan Li, Lina Wu, He Huang, Lingtong Meng   +12 more
wiley   +1 more source